test

Available Trials

Colorectal Cancer

10
A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer Refractory to Standard Therapies
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster
A Phase III, Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Disease/Condition: Colon
Principal Investigator: Sajid Khan
A Pilot Trial of KD018 with Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients with Locally Advanced Rectal Cancer
Disease/Condition: Rectum
Principal Investigator: Susan Higgins
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Disease/Condition: Anus | Colon
Principal Investigator: Neal Fischbach
A Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors
Disease/Condition: Breast - Female | Breast - Male | Colon
Principal Investigator: Melinda Irwin
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
Principal Investigator: Jennifer Choi
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Disease/Condition: Colon | Liver | Rectum
Principal Investigator: Howard Hochster
An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Phase Ib/II study of LGX818 and Cetuximab or LGX818, BYL719 and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster

Gastric and Esophageal

10
A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors
Disease/Condition: Esophagus | Stomach
Principal Investigator: Howard Hochster
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase II Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Disease/Condition: Esophagus | Other Digestive Organ
Principal Investigator: Jeremy Kortmansky
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Disease/Condition: Adenocarcinoma of the Gastroesophageal Junction | Esophagus | Gastric Cancer | Stomach
Principal Investigator: Howard Hochster
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Disease/Condition: Esophagus
Principal Investigator: Daniel Boffa

Liver Cancer

10
There are currently no trials available in this category.

Pancreatic Cancer